Literature DB >> 10639381

Molecular characterization of the beta-lactamases from clinical isolates of Moraxella (Branhamella) catarrhalis obtained from 24 U.S. medical centers during 1994-1995 and 1997-1998.

S S Richter1, P L Winokur, A B Brueggemann, H K Huynh, P R Rhomberg, E M Wingert, G V Doern.   

Abstract

The beta-lactamases from 403 Moraxella (Branhamella) catarrhalis clinical isolates obtained during 1994-1995 and 1997-1998 U.S. multicenter surveillance studies were characterized by isoelectric focusing. The overall prevalences of the BRO-1 and BRO-2 enzymes among beta-lactamase-positive isolates were estimated to be 97.5 and 2.5%, respectively. The minimum inhibitory concentrations (MICs) of ampicillin for all BRO-2-producing isolates were </=1 microg/ml; however, numerous beta-lactamase-positive isolates for which the ampicillin MICs were </=1 microg/ml produced the BRO-1 enzyme (88. 1%).

Entities:  

Mesh：

Substances：

Year:  2000        PMID： 10639381      PMCID： PMC89702          DOI： 10.1128/AAC.44.2.444-446.2000

Source DB:  PubMed          Journal:  Antimicrob Agents Chemother        ISSN： 0066-4804            Impact factor:   5.191


  13 in total

1.  A 1997-1998 national surveillance study: Moraxella catarrhalis and Haemophilus influenzae antimicrobial resistance in 34 US institutions.

Authors:  S S Richter; A B Brueggemann; H K Huynh; P R Rhomberg; E M Wingert; R Flamm; G V Doern
Journal:  Int J Antimicrob Agents       Date:  1999-10       Impact factor: 5.283

2.  Prevalence of antimicrobial resistance among 723 outpatient clinical isolates of Moraxella catarrhalis in the United States in 1994 and 1995: results of a 30-center national surveillance study.

Authors:  G V Doern; A B Brueggemann; G Pierce; T Hogan; H P Holley; A Rauch
Journal:  Antimicrob Agents Chemother       Date:  1996-12       Impact factor: 5.191

3.  Disk diffusion susceptibility of Branhamella catarrhalis and relationship of beta-lactam zone size to beta-lactamase production.

Authors:  I Luman; R W Wilson; R J Wallace; D R Nash
Journal:  Antimicrob Agents Chemother       Date:  1986-11       Impact factor: 5.191

4.  beta-Lactamases of Branhamella catarrhalis and their inhibition by clavulanic acid.

Authors:  T Farmer; C Reading
Journal:  Antimicrob Agents Chemother       Date:  1982-03       Impact factor: 5.191

5.  Detection, distribution and inhibition of Branhamella catarrhalis beta-lactamases.

Authors:  A Philippon; J Y Riou; M Guibourdenche; F Sotolongo
Journal:  Drugs       Date:  1986       Impact factor: 9.546

6.  BRO beta-lactamases of Branhamella catarrhalis and Moraxella subgenus Moraxella, including evidence for chromosomal beta-lactamase transfer by conjugation in B. catarrhalis, M. nonliquefaciens, and M. lacunata.

Authors:  R J Wallace; V A Steingrube; D R Nash; D G Hollis; C Flanagan; B A Brown; A Labidi; R E Weaver
Journal:  Antimicrob Agents Chemother       Date:  1989-11       Impact factor: 5.191

7.  Susceptibility of Moraxella catarrhalis isolates to beta-lactam antibiotics in relation to beta-lactamase pattern.

Authors:  C P Fung; S F Yeo; D M Livermore
Journal:  J Antimicrob Chemother       Date:  1994-02       Impact factor: 5.790

Review 8.  [beta-Lactamases of Branhamella catarrhalis and their phenotypic implications].

Authors:  E B Chaïbi; P Mugnier; M D Kitzis; F W Goldstein; J F Acar
Journal:  Res Microbiol       Date:  1995 Nov-Dec       Impact factor: 3.992

9.  Characterization of cell-bound papain-soluble beta-lactamases in BRO-1 and BRO-2 producing strains of Moraxella (Branhamella) catarrhalis and Moraxella nonliquefaciens.

Authors:  I Eliasson; C Kamme; M Vang; S G Waley
Journal:  Eur J Clin Microbiol Infect Dis       Date:  1992-04       Impact factor: 3.267

10.  Isoelectric focusing of beta-lactamases from sputum and middle ear isolates of Branhamella catarrhalis recovered in the United States.

Authors:  D R Nash; R J Wallace; V A Steingrube; P A Shurin
Journal:  Drugs       Date:  1986       Impact factor: 9.546
View more
  6 in total

1.  Production of BRO beta-lactamases and resistance to complement in European Moraxella catarrhalis isolates.

Authors:  Franz-Josef Schmitz; Andreas Beeck; Mirella Perdikouli; Mechthild Boos; Susanne Mayer; Sybille Scheuring; Karl Köhrer; Jan Verhoef; Ad C Fluit
Journal:  J Clin Microbiol       Date:  2002-04       Impact factor: 5.948

2.  Contemporary prevalence of BRO beta-lactamases in Moraxella catarrhalis: report from the SENTRY antimicrobial surveillance program (North America, 1997 to 2004).

Authors:  Lalitagauri M Deshpande; Helio S Sader; Thomas R Fritsche; Ronald N Jones
Journal:  J Clin Microbiol       Date:  2006-10       Impact factor: 5.948

3.  Hag mediates adherence of Moraxella catarrhalis to ciliated human airway cells.

Authors:  Rachel Balder; Thomas M Krunkosky; Chi Q Nguyen; Lacey Feezel; Eric R Lafontaine
Journal:  Infect Immun       Date:  2009-08-10       Impact factor: 3.441

4.  Efficacy of the 26-kilodalton outer membrane protein and two P5 fimbrin-derived immunogens to induce clearance of nontypeable Haemophilus influenzae from the rat middle ear and lungs as well as from the chinchilla middle ear and nasopharynx.

Authors:  Jennelle M Kyd; Allan W Cripps; Laura A Novotny; Lauren O Bakaletz
Journal:  Infect Immun       Date:  2003-08       Impact factor: 3.441

5.  Moraxella catarrhalis uses a twin-arginine translocation system to secrete the β-lactamase BRO-2.

Authors:  Rachel Balder; Teresa L Shaffer; Eric R Lafontaine
Journal:  BMC Microbiol       Date:  2013-06-19       Impact factor: 3.605

6.  Use of the Chinchilla model to evaluate the vaccinogenic potential of the Moraxella catarrhalis filamentous hemagglutinin-like proteins MhaB1 and MhaB2.

Authors:  Teresa L Shaffer; Rachel Balder; Sean W Buskirk; Robert J Hogan; Eric R Lafontaine
Journal:  PLoS One       Date:  2013-07-02       Impact factor: 3.240
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.